Release Date: 18-Sep-2021
US FDA has announced Orphan Drug Designation to aviptadil (RLF-100) for the treatment of sarcoidosis. Aviptadil is an inhaled, synthetic formulation of vasoactive intestinal peptide (VIP). Aviptadil is shown to preserve surfactant production, reduce inflammation in the lungs, and protect alveolar type II cells from injury.
The FDA’s Orphan Drug Program provides financial incentives to companies developing drugs for rare diseases and conditions. Through the program, eligible drugs can be granted tax credits and other benefits.
Sarcoidosis is a rare inflammatory disease characterized by the formation of granulomas in the body, mainly in the lungs and lymph nodes. The first trial is conducted with 20 patients with pulmonary sarcoidosis. Results showed that treatment with aviptadil was safe and well tolerated.